康芝藥業(300086.SZ)：擬售康芝醫院公司100%股權 不再持有九洲醫院和和萬家醫院各51%的股權
格隆匯6月18日丨康芝藥業(300086.SZ)公佈，公司於2021年6月18日召開第五屆董事會第十六次會議，審議通過了《關於公司出售廣東康芝醫院管理有限公司的100%股份暨間接出讓雲南九洲醫院有限公司和昆明和萬家婦產醫院有限公司各51%股權的議案》，公司擬以人民幣33966萬元出售廣東康芝醫院管理有限公司(“康芝醫院公司”或“廣州瑞瓴”)90%股權給天津濱海遠賢管理諮詢中心(有限合夥)及擬以人民幣3774萬元出售康芝醫院公司10%股權給四川錦欣生殖醫療投資管理有限公司。
此次交易完成後，公司將不再持有康芝醫院公司股權，暨不再持有云南九洲醫院有限公司(“九洲醫院”)和昆明和萬家婦產醫院有限公司(“和萬家醫院”)各51%的股權。
通過此次交易有助於公司整合及優化現有資源配置，調整生殖醫療服務的區域佈局，增加運營資金，從而提升上市公司整體競爭力。此次交易預計將產生5000多萬元的投資收益(最終收益數據以公司年度經審計的財務報吿為準)，對公司經營將產生一定的影響。
簽署此次交易協議的同時，公司也與錦欣生殖醫療集團有限公司簽署了《康芝藥業股份有限公司與錦欣生殖醫療集團有限公司戰略合作框架協議》，以建立密切、長久及融洽的戰略合作伙伴關係，充分發揮各自特長，在輔助生殖醫療服務合作，輔助生殖醫院投資佈局，母嬰健康業務區域市場合作開發，母嬰產品和兒童藥品的市場及客户網絡供應鏈，上市公司股權投資等開展合作，進一步提升整體運營效率和服務價值，降低運營成本，實現資源合作、優勢互補、共同發展。
公司此次交易，在獲得股權投資收益的同時，公司將與中國非國有輔助生殖有名企業錦欣生殖醫療集團有限公司建立戰略合作關係，繼續對生殖醫學領域進行區域佈局調整及尋找新的戰略機會，未來考慮重點戰略佈局海南自貿港和華南醫療核心區域，如廣州等珠三角地區；同時探討協助錦欣生殖醫療集團有限公司進行輔助生殖藥品耗材的技術引進與委託生產加工合作，共同打造醫療服務產業基地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
